ReviewWorld journal of diabetes2021
Cardiovascular autonomic neuropathy in diabetes: Pathophysiology, clinical assessment and implications.
Review in World journal of diabetes, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 2 syntheses or guidelines pooled it, 80 citations in OpenAlex.
- Association between continuous glucose monitoring metrics and cardiovascular autonomic neuropathy in diabetic patients: a systematic review.Reviews in endocrine & metabolic disorders · 2025Pooled it
- Prevalence and Risk Factors of Cardiovascular Autonomic Neuropathy in Individuals with Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis.Reviews in cardiovascular medicine · 2024Pooled it
- Effects of MCC950 on lipid profiles, glycemic control, and sympathetic dysfunction in a streptozotocin-induced type 1 diabetic rat model.Croatian medical journal · 2026Article
- Visit-to-visit systolic blood pressure variability, blood pressure treatment intensity, and cognitive decline.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Diagnostic accuracy of the COMPASS-31 orthostatic intolerance domain for detecting cardiovascular autonomic neuropathy in resource-limited settings.Cardiovascular diabetology. Endocrinology reports · 2026Article
- Body mass index, sedentary lifestyle, and HbA1c predict cardiac autonomic neuropathy in type 2 diabetes.Cardiovascular diabetology. Endocrinology reports · 2026Article
- Targeting risk factors and strategies for prevention of peripheral neuropathy: focus on B-vitamin deficiencies and metabolic diseases.Neurological research and practice · 2026Review
- Circulating Neopterin Is Independently Associated with Autonomic Neuropathy in Type 2 Diabetes, but Not with Other Microvascular Complications.Medical sciences (Basel, Switzerland) · 2026Article
- From Beat to Risk: How Heart Rate Variability Predicts Arrhythmias in Type 2 Diabetes.Life (Basel, Switzerland) · 2026Review
- Development and Pilot Evaluation of a Wearable 12-Lead ECG System for Multilead Feature Analysis in Individuals with Different Glycemic Status.Sensors (Basel, Switzerland) · 2026Article
- Electrophysiological diagnosis using the coefficient of variation of R-R intervals and a point-of-care nerve conduction device is highly correlated to the diagnosis of diabetic polyneuropathy using conventional electromyographs.Journal of diabetes investigation · 2026Article
- Sympathetic-like-integrated engineered heart tissue models AGEs-induced adverse remodeling.Cardiovascular diabetology · 2026Article
- Development and validation of a nomogram model for predicting cardiac autonomic neuropathy in patients with diabetes.Frontiers in endocrinology · 2026Article
- Dapagliflozin associates with heart rate variability decline in T2DM patients on GLP-1 receptor agonist therapy: a prospective observational study.Frontiers in endocrinology · 2026Observational
- Type 2 Diabetes Intensifies Nocturnal and Early Morning Circadian Autonomic Dysregulation After Ischaemic Stroke.Journal of diabetes research · 2026Article
- Fitness parameters as a marker of cardiac autonomic neuropathy among diabetes mellitus patients.Bioinformation · 2026Article
- Article
- U-shaped association of the stress hyperglycemia ratio with all-cause mortality and premature death in patients with cardiovascular disease: a cohort study.Diabetology & metabolic syndrome · 2025Article
- The neuronal imaging in cardiology: 123I-Biophysical reviews · 2025Review
- Changes in Autonomic Balance, Cardiac Parasympathetic Modulation, and Cardiac Baroreflex Gain in Older Adults Under Different Orthostatic Stress Conditions.Healthcare (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiovascular autonomic neuropathy (CAN) is a debilitating condition that mainly occurs in long-standing type 2 diabetes patients but can manifest earlier, even before diabetes is diagnosed. CAN is a microvascular complication that results from lesions of the sympathetic and parasympathetic nerve fibers, which innervate the heart and blood vessels and promote alterations in cardiovascular autonomic control. The entire mechanism is still not elucidated, but several aspects of the pathophysiology of CAN have already been described, such as the production of advanced glycation end products, reactive oxygen species, nuclear factor kappa B, and pro-inflammatory cytokines. This microvascular complication is an important risk factor for silent myocardial ischemia, chronic kidney disease, myocardial dysfunction, major cardiovascular events, cardiac arrhythmias, and sudden death. It has also been suggested that, compared to other traditional cardiovascular risk factors, CAN progression may have a greater impact on cardiovascular disease development. However, CAN might be subclinical for several years, and a late diagnosis increases the mortality risk. The duration of the transition period from the subclinical to clinical stage remains unknown, but the progression of CAN is associated with a poor prognosis. Several tests can be used for CAN diagnosis, such as heart rate variability (HRV), cardiovascular autonomic reflex tests, and myocardial scintigraphy. Currently, it has already been described that CAN could be detected even during the subclinical stage through a reduction in HRV, which is a non-invasive test with a lower operating cost. Therefore, considering that diabetes mellitus is a global epidemic and that diabetic neuropathy is the most common chronic complication of diabetes, the early identification and treatment of CAN could be a key point to mitigate the morbidity and mortality associated with this long-lasting condition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.